Ipca Laboratories Ltd's Q2FY17 standalone net profit rises 345.3% yoy to Rs.54.95 crore : Estimates Mixed

India Infoline Research Team | November 11, 2016 19:07 IST

Ipca Laboratories Ltd Q2FY17

Standalone Results Q2FY17: (Rs. in crore)

Q2FY17 YoY (%)
Revenue 885.06 17.4
EDITDA 128.03 52.3
EBITDA Margin (%) 14.5 332
Net Profit (adjusted) 54.95 345.3
***EBITDA margin change is bps


IPCA Laboratories Ltd’s Q2FY17 numbers came in mix bag with Bloomberg estimates. Revenue came in 3.5% higher than the estimate of Rs 855 cr. EBITDA margin was higher by 361 bps from the estimate of 11%. Net profit was reported 28% below than the estimated figure of Rs 76 cr.
Revenue for the quarter increased 17.4% yoy to Rs 885 cr.
Reported EBITDA surged 52.3% yoy to Rs 128 cr while EBITDA margins expanded by 331 bps yoy to 14%. This was largely due to operational efficiency.
Net profit jumped 345% yoy to Rs 54.95 cr, primarily due to foreign exchange gain of Rs 7.81 compared to loss of Rs 23.63 cr in Q2FY16.

Technical View:

Ipca Laboratories Ltd ended at Rs. 599.7, up by 7.2 points or 1.22% from its previous closing of Rs. 592.5 on the BSE.
The scrip opened at Rs. 585.9 and touched a high and low of Rs. 618 and Rs. 583.8 respectively. A total of 666552(NSE+BSE) shares were traded on the counter. The stock traded below its 50 DMA.

BSE 564.90 [6.70] ([1.17]%)
NSE 565.05 [9.10] ([1.58]%)

***Note: This is a NSE Chart

 

Advertisements

  • Get your free IIFL Demat & Trading A/c now...Click here
  • Get IIFL express personal loan disbursal in just 8* hours...Know More
  • Get the most detailed result analysis on the web - Real Fast!
  • Actionable & Award-Winning Research on 500 Listed Indian Companies.